Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/121636
Title: | Novel mutations associated with inherited human calcium-sensing receptor disorders: A clinical genetic study | Authors: | García-Castaño, Alejandro Madariaga, Leire Pérez de Nanclares, Gustavo Ariceta, Gema Gaztambide, Sonia Castaño, Luis Ramírez González, Juan Andrés Gómez Cabrera, María Milagrosa Montalban, C Ruiz, R Socias, C Boronat Cortés, Mauro Aparicio, C Alonso Bilbao, Ignacio Conde, S Garcia-Cuartero, B Jimenez, B Medina Rodríguez, Pedro Perez, E Hidalgo-Barquero, E Barrio, R Gonzalez, CM Cordo, CLR Cruz, J Hernandez, J Fernández-Ramos, C Marti, J Clemente, M Garcia, L Rica, I Martinez, R Urrutia, I de LaPiscina, IM Santos, F Gil-Pena, H Coto, E Loredo, V Ordonez, FA Rodriguez, J Riera, EB Hernandez, O Fuente, R Claramunt, D Nieto, VMG Martin, FC Acosta, HG Trujillo, ER Yanes, MIL Lanus, EC Castano, L Madariaga, L de Nanclares, GP Garcia-Castano, A Aguirre, M Campos Herrero Navas,María Isolina Aguayo, A Ariceta, G Meseguer, A Boronat M |
Issue Date: | 2019 | Journal: | European Journal of Endocrinology | Abstract: | Objective: Molecular diagnosis is a useful diagnostic tool in calcium metabolism disorders. The calcium-sensing receptor (CaSR) is known to play a central role in the regulation of extracellular calcium homeostasis. We performed clinical, biochemical and genetic characterization of sequence anomalies in this receptor in a cohort of 130 individuals from 82 families with suspected alterations in the CASR gene, one of the largest series described. Methods: The CASR gene was screened for mutations by polymerase chain reaction followed by direct Sanger sequencing. Results: Presumed CaSR-inactivating mutations were found in 65 patients from 26 families. These patients had hypercalcemia (median: 11.3 mg/dL) but normal or abnormally hig h parathyroid hormone (PTH) levels (median: 52 pg/ mL). On the other hand, presumed CaSR-activating mutations were detected in 17 patients from eight families. These patients had a median serum calcium level of 7.4 mg/dL and hypo parathyroidism (median: PTH 13 pg/mL). Further, common polymorphisms previously associated with high blood ionized calcium levels were found in 27 patients (median calcium: 10.6 mg/dL; median PTH: 65 pg/mL) with no othe r alterations in CASR. Overall, we found 30 different mutations, of which, 14 have not been previously reported (p.Ala26Ser, p.Cys60Arg, p.Lys119Ile, p.Leu123Met, p.Glu133Val, p.Gly222Glu, p.Phe351Ile, p.Cys542Tyr, p.Cys546Gly, p.Cys677Tyr, p.Ile816Val, p.Ala887Asp, p.Glu934*, p.Pro935_Gln945dup). Conclusions: Patients with CASR mutations may not fit the classic clinical pictures of hypercal cemia with hypocalciuria or hypocalcemia with hypercalciuria. Molecular studies are impo rtant for confirming the diagnosis and distinguishing it from other entities. Our genetic analysis confirmed CaSR disorde rs in 82 patients in the study cohort. | URI: | http://hdl.handle.net/10553/121636 | ISSN: | 0804-4643 | DOI: | 10.1530/EJE-18-0129 | Source: | European Journal of Endocrinology [ISSN 0804-4643], v. 180 (1), p. 59-70, (Enero 2019) |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
16
checked on Sep 8, 2024
WEB OF SCIENCETM
Citations
13
checked on Sep 8, 2024
Page view(s)
80
checked on Jul 27, 2024
Download(s)
71
checked on Jul 27, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.